#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17094	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2458	856.1	0	.	n	.	0	A69G	SNP	69	69	A	484	484	G	1085	G,A,T	1081,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17094	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2458	856.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1865	1865	T	1076	T,C,G	1071,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17094	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2458	856.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1599	1599	C	1137	C,A,T,G	1132,2,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29660	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4021	919.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1892	1892	A	1266	A,G,C	1263,1,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29660	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4021	919.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2526	2526	C	1067	C,T	1065,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29660	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4021	919.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2600	2600	A	996	A	995	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29660	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4021	919.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3152	3152	C	1071	C,A	1068,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	2550	folP	852	852	99.88	folP.l15.c4.ctg.1	1998	159.1	0	.	p	.	0	E151K	NONSYN	451	453	GAA	997	999	AAA	256;256;257	A,C;A,C,G;A,C,G	255,1;254,1,1;254,2,1	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	2550	folP	852	852	99.88	folP.l15.c4.ctg.1	1998	159.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1228	1230	AGC	269;270;270	A,T;G;C	268,1;270;270	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5992	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3826	195.1	1	SNP	p	S91F	0	.	.	271	273	TCC	798	800	TCC	220;220;220	T;C,A;C	220;219,1;220	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5992	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3826	195.1	1	SNP	p	D95G	0	.	.	283	285	GAC	810	812	GAC	217;218;220	G;A,T;C,A	217;217,1;219,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5992	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3826	195.1	1	SNP	p	D95N	0	.	.	283	285	GAC	810	812	GAC	217;218;220	G;A,T;C,A	217;217,1;219,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	2272	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1704	165.8	1	SNP	p	G45D	0	.	.	133	135	GGC	683	685	GGC	259;260;259	G;G;C	259;260;259	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1360	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1441	117.7	0	.	n	.	0	A197.	DEL	197	197	A	809	809	A	272	A	272	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6060	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3346	225.4	1	SNP	p	D86N	0	.	.	256	258	GAC	744	746	GAC	272;272;273	G;A,G;C,T	272;271,1;272,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6060	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3346	225.4	1	SNP	p	S87I	0	.	.	259	261	AGT	747	749	AGT	271;273;271	A,G;G;T	270,1;273;271	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6060	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3346	225.4	1	SNP	p	S87W	0	.	.	259	261	AGT	747	749	AGT	271;273;271	A,G;G;T	270,1;273;271	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6060	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3346	225.4	1	SNP	p	S87R	0	.	.	259	261	AGT	747	749	AGT	271;273;271	A,G;G;T	270,1;273;271	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6060	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3346	225.4	1	SNP	p	S88P	0	.	.	262	264	TCC	750	752	TCC	275;278;278	T;C;C	275;278;278	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5014	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3077	203.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1757	1759	GGC	265;265;266	G;G;C	265;265;266	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	0	.	p	.	0	K8E	NONSYN	22	24	AAG	595	597	GAG	183;185;188	G;A,C;G,A	183;184,1;187,1	.	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1504	1506	GCA	253;253;255	G,A;C;A	252,1;253;255	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1507	1509	ATC	256;255;251	A;T;C	256;255;251	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1519	1521	GTG	260;264;265	G,C;T;G,T	259,1;264;264,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1519	1521	GTG	260;264;265	G,C;T;G,T	259,1;264;264,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2023	2025	ACC	279;279;280	A,C,G;C;C,G	276,2,1;279;279,1	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2077	2079	GCG	270;271;272	G;C,G;G	270;270,1;272	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2077	2079	GCG	270;271;272	G;C,G;G	270;270,1;272	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2200	2202	GGC	263;263;261	G,C;G;C	261,1;262;260	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2209	2211	GGC	265;268;268	G,C;G;C	263,1;267;267	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4534	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2878	196.2	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2227	2229	CTG	270;269;271	C,G;T;G	269,1;269;271	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6488	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3499	231.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1818	1820	CCG	275;275;277	C,G,A;C;G,C	273,1,1;275;276,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2622	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2336	140.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	843	843	C	190	C	190	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	93	94.62	porB1a.l15.c17.ctg.2	175	55.3	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	62;61;61	A;C;G	62;61;61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	13	15	TTA	20;22;23	T;T;A	20;22;23	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	58	60	CAT	61;61;61	C;A;T	61;61;61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	61	63	AGT	61;61;61	A;G;T	61;61;61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	70	72	TAC	61;61;61	T;A;C	61;61;61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	R307A	NONSYN	919	921	AGA	160	162	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	172	174	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	E312D	NONSYN	934	936	GAA	175	177	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	181	183	ATC	3;3;4	A;T;C	3;3;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	187	189	TCG	4;4;4	T;C;G	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	193	195	GCC	4;5;5	G;C;C	4;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	196	198	AGC	5;5;5	A;G;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	199	201	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	314	porB1a	984	222	90.54	porB1a.l15.c17.ctg.3	307	30.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	205	207	GTT	6;6;6	G;T;T	6;6;6	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3352	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1731	236.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	483	485	GAA	299;308;308	G;A,G,C;A,T	299;306,1,1;307,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3352	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1731	236.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	771	773	GAT	302;302;304	G;A,C;T,G	302;301,1;302,2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3352	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1731	236.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	894	896	TCA	307;311;311	T;C;A,G	307;311;310,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3352	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1731	236.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1023	1025	GTC	270;269;271	G,T;T;C	269,1;269;271	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3352	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1731	236.9	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1035	1037	TCT	274;276;280	T;C;T	274;276;280	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3352	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1731	236.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1353	1355	GCA	271;273;270	G;C;A	271;273;270	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3352	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1731	236.9	1	SNP	p	G120K	1	.	.	358	360	AAG	729	731	AAG	288;289;291	A,C;A;G,A	287,1;289;290,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3352	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1731	236.9	1	SNP	p	D121N	0	.	.	361	363	GAC	732	734	GAC	289;290;289	G,T;A;C	288,1;290;289	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3352	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1731	236.9	1	SNP	p	A121D	1	.	.	361	363	GAC	732	734	GAC	289;290;289	G,T;A;C	288,1;290;289	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11620	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5261	275.1	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2163	2165	AAT	320;322;322	A;A,T;T	320;321,1;322	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1668	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1438	144.2	1	SNP	p	V57M	1	.	.	169	171	ATG	789	791	ATG	310;309;310	A,T;T,G;G	309,1;308,1;310	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
